Teva terminates CureTech collaboration

Teva will write off $109 million on its CureTech investment, which is developing a drug for hematological cancers.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced the termination of its collaboration with CureTech Ltd.

Teva president and CEO R&D and chief R&D officer Dr. Michael Hayden said, "We are in the process of conducting a disciplined review of our pipeline. As we looked closely at CT‐011 and the most recent clinical and biochemical data, we have made the strategic decision to invest our resources elsewhere where we can have the most impact for patients.”

CT‐011 is a monoclonal antibody being developed as a treatment for hematological malignancies and solid tumors. CT‐011 was assessed in several phase I and II clinical studies in various cancer indications including diffuse large B‐cell lymphoma (DLBCL), colon cancer, metastatic melanoma and additional investigator initiated studies.

Teva entered into agreements with CureTech in 2006. Teva now intends to book a noncash net charge of $109 million as a result of the impairment of its investment in CureTech.

Published by Globes [online], Israel business news - www.globes-online.com - on January 31, 2013

© Copyright of Globes Publisher Itonut (1983) Ltd. 2013

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
MORE FROM GLOBES
Twitter Facebook Linkedin RSS Newsletters גלובס